EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy

Colleen R Foley iD, Sheridan L Swan iD, Melody A Swartz

The Journal of Immunology · 2024

DOI: 10.4049/jimmunol.2300642 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Immunology, 2024. Verfasst von Colleen R Foley und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL. Hauptthemen laut MEDLINE: Neoplasms, Vaccines, Cancer Vaccines. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 189 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | NIH | National Cancer Institute (NCI), HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of a patient’s own immune or tumor cells, manipulated ex vivo, enables Ag- or patient-specific immunotherapy. Despite some clinical successes, there remain significant barriers to efficacy, broad patient population applicability, and safety. Immunotherapies that target specific tumor Ags, such as chimeric Ag receptor T cells and some dendritic cell vaccines, can mount robust immune responses against immunodominant Ags, but evolving tumor heterogeneity and antigenic downregulation can drive resistance. In contrast, whole tumor cell vaccines and tumor lysate-loaded dendritic cell vaccines target the patient’s unique tumor antigenic repertoire without prior neoantigen selection; however, efficacy can be weak when lower-affinity clones dominate the T cell pool. Chimeric Ag receptor T cell and tumor-infiltrating lymphocyte therapies additionally face challenges related to genetic modification, T cell exhaustion, and immunotoxicity. In this review, we highlight some engineering approaches and opportunities to these challenges among four classes of autologous cell therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsVaccinesCancer VaccinesHumansAntigens, NeoplasmT-LymphocytesImmunotherapyDendritic CellsImmunotherapy, Adoptive

Substanzen

Antigens, NeoplasmVaccinesCancer Vaccines

Autor:innen und Institutionen

  • Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL.
  • Committee on Immunology, University of Chicago, Chicago, IL.
  • Ben May Department for Cancer Research, University of Chicago, Chicago, IL.

ORCID-Profile: Colleen R Foley, Sheridan L Swan

Förderung

  • NIAID NIH HHS
  • HHS | NIH | National Cancer Institute (NCI)
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  • NCI NIH HHS

Zitieren

APA

Foley, C. R., Swan, S. L., & Swartz, M. A. (2024). Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2300642

Vancouver

Foley CR, Swan SL, Swartz MA. Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy. The Journal of Immunology. 2024. doi:10.4049/jimmunol.2300642

BibTeX
@article{Foley2024,
  author = {Foley, Colleen R and Swan, Sheridan L and Swartz, Melody A},
  title = {Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy},
  journal = {The Journal of Immunology},
  year = {2024},
  doi = {10.4049/jimmunol.2300642}
}
Kostenlos starten →